Akademik Veri Yönetim Sistemi
JOURNAL OF CARDIAC SURGERY, cilt.2025, sa.1, 2025 (SCI-Expanded, Scopus)
Objective: This study compared early postoperative outcomes of Custodiol-HTK versus cold intermittent blood cardioplegia in patients undergoing complete atrioventricular septal defect (CAVSD) repair. Methods: From January 2012 to December 2022, we retrospectively analyzed 305 patients undergoing CAVSD repair at our center. Patients were divided into two groups based on cardioplegia: Group 1 received Custodiol-HTK (n = 159), and Group 2 received cold intermittent blood cardioplegia (n = 146). Outcomes that were compared included mortality, ECMO requirement, cross-clamp and cardiopulmonary bypass (CPB) times, cardioplegia doses, valvular edema (assessed intraoperatively via a visual scale), postoperative intubation time, ICU stay, and hospital stay. Results: Mortality was 1.9% in Group 1 versus 8.2% in Group 2 (p = 0.01). ECMO was required in 0.6% of Group 1 versus 11.0% of Group 2 (p < 0.001). Cross-clamp time (56 +/- 12 min vs. 76 +/- 16 min, p < 0.001) and CPB time (83 +/- 14 min vs. 97 +/- 17 min, p = 0.002) were shorter in Group 1. Cardioplegia doses were 1 in Group 1 versus 4.7 +/- 1.2 in Group 2 (p < 0.001). Intubation time, ICU stay, and hospital stay were significantly shorter in Group 1 (p < 0.01 for each). Conclusion: Custodiol-HTK was associated with improved early outcomes, including reduced mortality, ECMO use, and shorter operative and recovery times, in CAVSD repair. It appears to offer superior myocardial protection, particularly in complex cases, though potential risks such as hyponatremia require careful perioperative management.